A whole new era of cancer therapeutics has dawned with the continuing success of STI571 in chronic myelogenous leukemia (CML), according to cancer experts at the annual meeting of the American Society of Hematology (ASH) in San Francisco. "This drug represents a new paradigm for cancer therapy, to identify specific abnormalities and then to target therapies for all cancers," said Brian Druker, professor of medicine at the Oregon Health Sciences University in Portland, OR. "It took 40 years of understanding the molecular genesis of CML to develop a therapeutically targeted agent.
Go to Previous Page
Go to Next Page